Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Next-Generation Cancer Immunotherapy Targeting Glypican-3.
Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T. Shimizu Y, et al. Among authors: nakatsura t. Front Oncol. 2019 Apr 10;9:248. doi: 10.3389/fonc.2019.00248. eCollection 2019. Front Oncol. 2019. PMID: 31024850 Free PMC article. Review.
Single-cell analysis of T-cell receptor repertoire of HTLV-1 Tax-specific cytotoxic T cells in allogeneic transplant recipients with adult T-cell leukemia/lymphoma.
Tanaka Y, Nakasone H, Yamazaki R, Sato K, Sato M, Terasako K, Kimura S, Okuda S, Kako S, Oshima K, Tanihara A, Nishida J, Yoshikawa T, Nakatsura T, Sugiyama H, Kanda Y. Tanaka Y, et al. Among authors: nakatsura t. Cancer Res. 2010 Aug 1;70(15):6181-92. doi: 10.1158/0008-5472.CAN-10-0678. Epub 2010 Jul 20. Cancer Res. 2010. PMID: 20647322
HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, Motomura Y, Tanaka Y, Hayashi S, Nakatsura T. Yoshikawa T, et al. Among authors: nakatsura t. Cancer Sci. 2011 May;102(5):918-25. doi: 10.1111/j.1349-7006.2011.01896.x. Epub 2011 Mar 4. Cancer Sci. 2011. PMID: 21281401 Free article. Clinical Trial.
Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
Nobuoka D, Motomura Y, Shirakawa H, Yoshikawa T, Kuronuma T, Takahashi M, Nakachi K, Ishii H, Furuse J, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kinoshita T, Komori H, Baba H, Fujiwara T, Nakatsura T. Nobuoka D, et al. Among authors: nakatsura t. Int J Oncol. 2012 Jan;40(1):63-70. doi: 10.3892/ijo.2011.1202. Epub 2011 Sep 15. Int J Oncol. 2012. PMID: 21922136 Clinical Trial.
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T. Sawada Y, et al. Among authors: nakatsura t. Clin Cancer Res. 2012 Jul 1;18(13):3686-96. doi: 10.1158/1078-0432.CCR-11-3044. Epub 2012 May 10. Clin Cancer Res. 2012. PMID: 22577059 Clinical Trial.
141 results